Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Browse the world's most comprehensive archive of hedge fund manager letters. Access primary source research from leading institutional managers, sorted by reporting period.
Market performance is highly concentrated in expensive, low-dividend megacaps driven by volatile buybacks. Historical cycles suggest this trend is unsustainable and will mean-revert to smaller-cap and value stocks. Investors should avoid chasing overvalued megacaps and instead focus on resilient, high-yield dividend stocks to achieve superior risk-adjusted returns and lower volatility in an uncertain macroeconomic environment.
Full Quick Take
Market performance is highly concentrated in expensive, low-dividend megacaps driven by volatile buybacks. Historical cycles suggest this trend is unsustainable and will mean-revert to smaller-cap and value stocks. Investors should avoid chasing overvalued megacaps and instead focus on resilient, high-yield dividend stocks to achieve superior risk-adjusted returns and lower volatility in an uncertain macroeconomic environment.
Patient Capital's Opportunity Equity Strategy achieved a 25.23% net return in 2024, capitalizing on a late-year rally. The fund remains constructive on the ongoing technological revolution while actively rotating capital away from high-flying cyclicals into neglected pockets of deep value, healthcare, and energy.
Full Quick Take
Patient Capital's Opportunity Equity Strategy achieved a 25.23% net return in 2024, capitalizing on a late-year rally. The fund remains constructive on the ongoing technological revolution while actively rotating capital away from high-flying cyclicals into neglected pockets of deep value, healthcare, and energy.
